Cellosaurus logo
expasy logo

Cellosaurus KP-N-YS (CVCL_1342)

[Text version]
Cell line name KP-N-YS
Synonyms KPNYS; Kyoto Pediatrics-Neuroblastoma-YS
Accession CVCL_1342
Resource Identification Initiative To cite this cell line use: KP-N-YS (RRID:CVCL_1342)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Population: Japanese.
Microsatellite instability: Stable (MSS) (Sanger).
Omics: CRISPR phenotypic screen.
Omics: Deep exome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Derived from site: Metastatic; Bone marrow; UBERON=UBERON_0002371.
Sequence variations
  • Mutation; HGNC; 11998; TP53; Simple; p.Cys135Phe (c.404G>T); ClinVar=VCV000376559; Zygosity=Homozygous (Cosmic-CLP).
Genome ancestry Source: PubMed=30894373

Origin% genome
African0
Native American1.29
East Asian, North74.96
East Asian, South23.74
South Asian0
European, North0
European, South0
Disease Adrenal gland neuroblastoma (NCIt: C4827)
Neuroblastoma (ORDO: Orphanet_635)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_Y132 (KP-N-YS1n)CVCL_Y133 (KP-N-YS2s)
Sex of cell Male
Age at sampling 4Y
Category Cancer cell line
STR profile Source(s): Cosmic-CLP

Markers:
AmelogeninX,Y
CSF1PO10,11
D5S8189,13
D7S82010,12
D13S3178,12
D16S53910
TH017
TPOX9,11
vWA14

Run an STR similarity search on this cell line
Publications

PubMed=10363161
Yagi M., Sugimoto T., Mine H., Horii Y., Matsumura T., Sawada T., Abe T., Sano K., Goshi J., Takahashi K.
Basic calponin expressing human neuroblastoma cell line of KP-N-YS.
Hum. Cell 11:231-238(1998)

PubMed=11129446; DOI=10.1097/00019606-200012000-00007
Sugimoto T., Mine H., Horii Y., Takahashi K., Nagai R., Morishita R., Komada M., Asada Y., Sawada T.
Neuroblastoma cell lines showing smooth muscle cell phenotypes.
Diagn. Mol. Pathol. 9:221-228(2000)

PubMed=12702577
Saito-Ohara F., Imoto I., Inoue J., Hosoi H., Nakagawara A., Sugimoto T., Inazawa J.
PPM1D is a potential target for 17q gain in neuroblastoma.
Cancer Res. 63:1876-1883(2003)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=23268333; DOI=10.1016/j.canlet.2012.12.011
Sugimoto T., Gotoh T., Yagyu S., Kuroda H., Iehara T., Hosoi H., Ohta S., Ohira M., Nakagawara A.
A MYCN-amplified cell line derived from a long-term event-free survivor among our sixteen established neuroblastoma cell lines.
Cancer Lett. 331:115-121(2013)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

CLPUB00582
Sugimoto T., Kuroda H., Yagyu S., Gotoh T., Osone S., Tamura S., Iehara T., Hosoi H.
Cellular and molecular characteristics of established neuroblastoma cell lines.
J. Cancer Res. Therap. Oncol. 7:201.1-201.15(2019)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=30971826; DOI=10.1038/s41586-019-1103-9
Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M., Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R., Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P., van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L., Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Nature 568:511-516(2019)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

Cross-references
Cell line databases/resources CLO; CLO_0037080
cancercelllines; CVCL_1342
Cell_Model_Passport; SIDM00157
CGH-DB; 82-1
CGH-DB; 9083-4
Cosmic-CLP; 946363
DepMap; ACH-002261
LINCS_LDP; LCL-1986
CRISP screens repositories BioGRID_ORCS_Cell_line; 916
Chemistry resources ChEMBL-Cells; CHEMBL3308266
ChEMBL-Targets; CHEMBL2366065
GDSC; 946363
PharmacoDB; KPNYS_789_2019
PubChem_Cell_line; CVCL_1342
Encyclopedic resources Wikidata; Q54900406
Gene expression databases ArrayExpress; E-MTAB-783
GEO; GSM1670008
Polymorphism and mutation databases Cosmic; 946363
IARC_TP53; 27174
Proteomic databases PRIDE; PXD030304
Entry history
Entry creation04-Apr-2012
Last entry update30-Jan-2024
Version number35